Tatyana Feldman, MD, discusses the TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Tatyana Feldman, MD
Advertisement
Articles by Tatyana Feldman, MD
Tatyana Feldman, MD, discusses the launch of the TRANSCEND CLL 004 trial in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Tatyana Feldman, MD, discusses updated safety and efficacy data from the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Tatyana Feldman, discusses the efficacy of adding etoposide to brentuximab vedotin followed by brentuximab vedotin consolidation in patients with newly diagnosed, CD30-expressing peripheral T-cell lymphomas.
Tatyana Feldman, MD, discusses the utility of PET Scan in Hodgkin Lymphoma.
Tatyana Feldman, MD, discusses the shortcomings of PET scan in Hodgkin lymphoma.
Dr. Tatyana Feldman, from the John Theurer Cancer Center, Discusses Using Doxil for CTCL
Dr. Tatyana Feldman from John Theurer Cancer Center Discusses the Difficulties of Rare Lymphomas
Advertisement
Latest Updated Articles
Dr. Feldman Discusses Using Doxil for CTCLPublished: December 19th 2011 | Updated:
Dr. Feldman on the Shortcomings of PET Scan in Hodgkin LymphomaPublished: March 26th 2020 | Updated:
Dr. Feldman on the Utility of PET Scan in Hodgkin LymphomaPublished: April 23rd 2020 | Updated:
Dr. Feldman Discusses the Difficulties of Rare LymphomasPublished: December 10th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
5